pyrroles and Stroke
pyrroles has been researched along with Stroke in 182 studies
Research
Studies (182)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 108 (59.34) | 29.6817 |
| 2010's | 72 (39.56) | 24.3611 |
| 2020's | 2 (1.10) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, J; Lan, X; Liu, X; Song, D; Xue, J; Zhang, L; Zhang, X | 1 |
| Feng, W; Islam, SMT; Khan, M; Kumar, P; Qiao, F; Singh, AK; Singh, I; Won, JS | 1 |
| Chen, Q; Guan, F; Li, M; Wang, J; Wang, W; Wang, Y; Wang, Z; Zhang, W | 1 |
| Bliss, TM; George, PM; Hua, T; Lee, A; Levinson, A; Mehta, S; Oh, B; Steinberg, GK; Sun, G | 1 |
| Cho, S; Kim, E; Park, KW; Yang, J | 1 |
| George, P; Oh, B | 1 |
| Biswas, P; Boy, MG; Charles-Schoeman, C; DeMasi, R; Hwang, LJ; McInnes, IB; Soma, K; Valdez, H | 1 |
| Delgado, G; Naves, M | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Bordet, R; Darteil, R; Duriez, P; Gautier, S; Hanf, R; Laprais, M; Ouk, T; Potey, C; Staels, B | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Albers, GW; Tai, WA | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Ovbiagele, B; Sillesen, H; Welch, KM; Zivin, J | 1 |
| Cao, Z; Feng, Y; Gao, P; Lu, Z; Wang, P; Wang, S; Zhang, G; Zhou, P | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Amarenco, P; Callahan, A; Campese, VM; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Wilson, DJ; Zivin, JA | 1 |
| Giacomini, P; Izzo, C; Manuppella, F; Marchione, P; Maugeri, A; Morreale, M; Romeo, T; Vento, C | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Abdel-Rahman, I; Murphy, C | 1 |
| Brown, CE; Gerrow, K; Holmes, A; Lockhart, KL; Nahirney, PC; Reeson, P; Tennant, KA; Thompson, K; Wang, J; Weiser Novak, S | 1 |
| Bangalore, S; Breazna, A; DeMicco, DA; Messerli, FH; Wun, CC | 1 |
| Fabiny, A | 1 |
| Ago, T; Arimura, K; Kamouchi, M; Kitazono, T; Kuroda, J; Makihara, N; Nakamura, K; Nishimura, A; Ooboshi, H; Tachibana, M; Wakisaka, Y; Yoshikawa, Y | 1 |
| Chen, Q; Deng, G; Li, M; Li, Q; Wan, J; Wang, J; Wang, W; Wang, Y; Yang, Q | 1 |
| Aebischer, B; Akboga, MK; Akdamar, G; Alcalay, RN; Álvarez-Pérez, S; Aydogdu, S; Balci, KG; Barcaro, G; Bišová, K; Blanco, JL; Brewer, SH; Caruthers, SD; Ceylan, O; Chadwick, JA; Chang, DD; Che, JM; Chen, QQ; Chen, W; Chen, Z; Chung, M; Chung, W; Colecraft, HM; Coteli, E; Dogan, H; Dong, S; Elsig, S; Fahn, S; Fang, XJ; Feng, MG; Fenlon, EE; Floyd, KT; Fokdal, L; Ford, B; Fortunelli, A; Freudenberg, R; Gan-Or, Z; García, ME; Gillham, C; Giovannelli, D; Goertz, RS; Gulati, V; Haie-Meder, C; Hao, YY; Hatano, K; Hines, KJ; Hines, SM; Hirakawa, H; Hoskin, P; Hu, JH; Huang, P; Huang, Y; Hubicka, U; Inoue, Y; Ishii, N; Janssen, PM; Jin, Z; Johnson, A; Jürgenliemk-Schultz, I; Kaineder, K; Kamei, K; Kang, U; Karatas, F; Kash, TL; Katayama, Y; Keupp, J; Kirisits, C; Kisacik, H; Kodama, K; Kotzerke, J; Kryczyk, A; Kuhness, D; Kuo, S; Lanza, GM; Le Bris, N; Levin, DE; Levy, OA; Li, B; Li, H; Li, X; Liang, GD; Liang, Y; Liao, RQ; Lin, JT; Lindegaard, JC; Liong, C; Liu, B; Liu, C; Liu, GH; Liu, L; Liu, Q; Liu, X; Lowe, J; Lowery-Gionta, EG; Ma, YH; Maden, O; Mankad, V; Marder, KS; Marshall, SA; Martínez-Nevado, E; Maucksch, U; Mazeron, R; Mazzone, CM; Mazzoni, P; Mezricky, D; Mizokami, Y; Naumann, A; Navarro, M; Netzer, FP; Neurath, MF; Nie, Q; Oliva, P; Ozeke, O; Peláez, T; Pfeifer, L; Pleil, KE; Pomp, S; Pötter, R; Puckerin, AA; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Řezanka, M; Řezanka, T; Rinker, JA; Rouleau, GA; Runge, R; Sahin, MD; Sakai, A; Schmieder, AH; Schmitz, AJ; Schultz, EJ; Šegedin, B; Sementa, L; Shen, Y; Shiotsuki, I; Shirahama, M; Staley, J; Starovoytov, V; Sterrer, M; Strobel, D; Sturdza, A; Subramanyam, P; Surnev, S; Swager, SA; Taeymans, J; Tan, H; Tan, LT; Tanderup, K; Temizhan, A; Terao, T; Thiele, TE; Tran, T; Tucker, MJ; Vetriani, C; Vítová, M; Wang, JP; Wang, L; Wang, M; Wang, X; Waters, CH; Weng, SX; Wickline, SA; Wildner, D; Wodarcyk, AJ; Wolf, P; Wu, L; Wu, YL; Wunderlich, G; Xiong, L; Xu, P; Yang, GS; Yang, XN; Yang, Y; Yayla, C; Ying, SH; Zachleder, V; Zhang, XG; Zhang, XK; Zhang, Y; Zheng, JY; Zhong, WZ; Zhu, J; Zhu, YJ; Żmudzki, P | 1 |
| Keppel Hesselink, JM | 1 |
| Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K | 1 |
| Deedwania, P; Singh, V | 1 |
| Amarenco, P; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, M; Lamonte, M; Messig, M; Sillesen, H; Welch, KM | 1 |
| Császár, A | 1 |
| Kim, YH; Kim, YJ; Lee, SH; Yoon, BW | 1 |
| Amarenco, P; Breazna, A; Callahan, A; Chaturvedi, S; Goldstein, LB; Hennerici, M; Rudolph, A; Sillesen, H; Welch, MA; Zivin, J | 1 |
| Fitchett, DH; Goodman, SG; Langer, A | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; O'Neill, BJ; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Martinez, DG | 1 |
| Caínzos Romero, T; Fernández Fernández, FJ; Pía Iglesias, G; Sesma, P | 1 |
| Hopkins, LN; Levy, EI; Samuelson, RM; Siddiqui, AH | 1 |
| Hanhart, J; Koskas, P; Le Mer, Y; Obadia, M; Paques, M; Sahel, JA | 1 |
| Hart, RG | 1 |
| Amarenco, P; Benavente, O; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, MG; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Coull, BM; Johnston, SC | 1 |
| Chen, TY; Kuo, YL; Lin, WC; Tan, TY | 1 |
| Amarenco, P; Brenner, D; Gongora-Rivera, F; Jaramillo, A; Klein, IF; Labreuche, J; Lavallée, PC; Touboul, PJ; Vicaut, E | 1 |
| Dahlof, B; Poulter, NR; Sever, PS; Wedel, H | 2 |
| Karadağ, B; Ongen, Z; Yilmaz, Y | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; O'Neill, BJ; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Caro, JJ; Kongnakorn, T; O'Brien, JA; Proskorovsky, I; Roberts, CS; Ward, A | 1 |
| Welch, KM | 1 |
| Tsuda, K | 1 |
| Myint, PK; Niruban, A; Potter, JF | 1 |
| Castilla-Guerra, L; Chaturvedi, S; Fernandez-Moreno, Mdel C; Jimenez-Hernandez, MD | 1 |
| Chaturvedi, S; Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Chopp, M; Cui, Y; Jia, L; Lu, M; Zhang, L; Zhang, ZG | 1 |
| Landau, W | 1 |
| Strupp, M | 1 |
| Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Nissen, SE | 1 |
| Derugin, N; Ferriero, DM; Shimotake, J; Vexler, ZS; Wendland, M | 1 |
| Amarenco, P; Benavente, O; Callahan, A; Goldstein, LB; Hennerici, MG; Sillesen, H; Welch, KM; Zivin, JA; Zweifler, RM | 1 |
| Cui, L; Du, W; Li, M; Liu, L; Wang, L; Yang, R; Zhang, X | 1 |
| Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J | 1 |
| Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K | 1 |
| Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R | 1 |
| Tuttle, KR | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K; Wierzbicki, AS | 1 |
| Huisa, BN; Stemer, AB; Zivin, JA | 1 |
| Boaz, M; Gilad, R; Lampl, Y; Lorberboym, M; Sadeh, M; Tikozky, A; Vysberg, I | 1 |
| Kamran, KA; Khan, M | 1 |
| Arrospide, A; Caro, J; Mar, J; Rejas-Gutiérrez, J; Vivancos-Mora, J | 1 |
| Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X | 1 |
| Gaur, V; Kumar, A | 1 |
| Frey, P; Waters, DD | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Arsenault, BJ; Bao, W; Barter, P; Deedwania, P; DeMicco, DA; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Preston, GM; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T | 1 |
| Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C | 1 |
| Djoussé, L; Gaziano, JM; Rahilly-Tierney, C; Sesso, HD | 1 |
| Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA | 1 |
| Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG | 1 |
| Kasner, SE; Taylor, RA; Weigele, JB | 1 |
| Sillence, D; Tchan, M | 1 |
| Altafullah, I; Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Ledbetter, LY; MacLeod, MJ; Messig, M; Samsa, GP; Scott, R; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P | 1 |
| Fagan, SC; Guan, W; Kozak, A | 1 |
| Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Ageno, W; Dentali, F; Romualdi, E; Squizzato, A | 1 |
| Braunwald, E | 1 |
| Shinohara, Y | 1 |
| Binning, MJ; Darkhabani, Z; Levy, EI; Mokin, M; Siddiqui, AH | 1 |
| Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB | 1 |
| Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES | 1 |
| Arsenault, BJ; Boekholdt, SM; Breazna, A; Deedwania, P; Demicco, DA; Kastelein, JJ; Mora, S; Waters, DD; Wenger, NK | 1 |
| Blanco, M; Castillo, J; Pérez-Mato, M; Rodríguez-Yáñez, M; Sobrino, T | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Munshi, A | 1 |
| Waeber, C; Wang, QM; Wei, Y; Zheng, Y | 1 |
| Degnan, AJ; Gillard, JH; Howarth, SP; Patterson, AJ; Tang, TY | 1 |
| Ali, S; Iyer, RS; Krishnan, M; Kumar, S | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Spence, JD | 1 |
| Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A | 1 |
| Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Symeonidis, AN | 1 |
| Hirooka, Y; Kishi, T; Mukai, Y; Shimokawa, H; Takeshita, A | 1 |
| Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Lindauer, U; Nickenig, G | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Baumgartner, RW; Georgiadis, D | 1 |
| Clark, LT | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 3 |
| SoRelle, R | 1 |
| Chen, J; Chopp, M; Feldkamp, CS; Jiang, H; Katakowski, M; Li, Y; Lu, M; Wang, L; Wang, Y; Zhang, C; Zhang, ZG | 1 |
| Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, AS; Goldstein, L; Hennerici, M; Sillsen, H; Welch, MA; Zivin, J | 1 |
| Brown, WV; Moussa, M | 1 |
| Guyton, JR; Herrington, DM; McGowan, MP; Shear, C; Waters, DD; Wenger, NK | 1 |
| Gathof, BS; Gresser, U | 1 |
| Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R | 1 |
| Hayashi, A; Ogawa, Y; Sasamata, M; Sonoda, R; Suzuki, M | 1 |
| Madsen, S | 1 |
| McGowan, MP | 1 |
| Chen, J; Chopp, M; Jiang, H; Katakowski, M; Li, Y; Lu, M; Robin, A; Zhang, C; Zhang, L | 1 |
| Griebenow, R | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Amin-Hanjani, S; Asahi, M; Huang, PL; Huang, Z; Liao, JK; Lo, EH; Mori, T; Moskowitz, MA; Qiu, J; Sumii, T; Thomas, S; Yoshimura, S | 1 |
| Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Jaber, BL; Madias, NE | 1 |
| Amarenco, P; Labreuche, J; Lavallée, PC; Touboul, PJ | 1 |
| Clearfield, M | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Lesaffre, E; Rizopoulos, D; Tsonaka, R | 1 |
| Chopp, M; Ding, G; Ewing, JR; Jiang, Q; Li, L; Panda, S; Zhang, L; Zhang, ZG | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Kent, DM | 1 |
| Brummel-Ziedins, KE; Bryniarski, L; Mann, KG; Potaczek, DP; Stobierska-Dzierzek, B; Szczeklik, A; Undas, A | 1 |
| Carod-Artal, FJ | 1 |
| Fitchett, DH; Goodman, SG; Langer, A; Leiter, LA | 1 |
| Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA | 1 |
| Cohen, JS | 1 |
| Khan, NA | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Elkind, MS | 1 |
| East, JE | 1 |
| Heering, NJ | 1 |
| Kulbertus, H | 1 |
| Katayama, Y; Katsumata, T; Nishiyama, Y; Otori, T; Tanaka, N | 1 |
| Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC | 1 |
| Blanco, M; Castellanos, M; Castillo, J; Dávalos, A; García-Gil, M; Leira, R; Lizasoain, I; Moro, MA; Nombela, F; Rodriguez-Yáñez, M; Serena, J; Vivancos, J | 1 |
| Bassi, A; Caltagirone, C; Colivicchi, F; Santini, M | 1 |
| Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M | 1 |
| Arca, M | 1 |
| Arca, M; Gaspardone, A | 1 |
| Amarenco, P | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Waters, DD | 1 |
| Armani, A; Toth, PP | 1 |
| Chen, J; Chopp, M; Cui, X; Li, A; Lu, M; Roberts, C; Zacharek, A | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
| Karam, JG; Loney-Hutchinson, L; McFarlane, SI | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Bonnaire, B; Bugnicourt, JM; Garcia, PY; Godefroy, O; Lefranc, M; Lepage, L | 1 |
| Crook, MA; Mikhailidis, DP; Wierzbicki, AS; Winder, AF | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Basson, CT; Delanty, N; Vaughan, CJ | 1 |
Reviews
24 review(s) available for pyrroles and Stroke
| Article | Year |
|---|---|
Conductive polymers to modulate the post-stroke neural environment.
Topics: Animals; Cell Differentiation; Electric Conductivity; Humans; Polymers; Pyrroles; Recovery of Function; Stroke; Stroke Rehabilitation | 2019 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; Animals; Animals, Zoo; Anti-Bacterial Agents; Anticoagulants; Antifungal Agents; Antimanic Agents; Antioxidants; Aortic Valve; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bacillus; Bacterial Toxins; Bacterial Typing Techniques; Base Composition; Beauveria; Binge Drinking; Biomarkers; Bipolar Disorder; Blood Coagulation; Blotting, Western; Brachytherapy; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Wall; Cells, Cultured; Ceramics; Chi-Square Distribution; China; Chlorophyll; Chlorophyta; Chloroplasts; Cholesterol, HDL; Chromatography, High Pressure Liquid; Chromobacterium; Clostridium perfringens; Clozapine; Constriction, Pathologic; Coronary Artery Bypass; Corticotropin-Releasing Hormone; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Dental Porcelain; Dental Restoration Failure; Dental Stress Analysis; Designer Drugs; Diaminopimelic Acid; DNA Fingerprinting; DNA, Bacterial; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Dosage Calculations; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Elasticity Imaging Techniques; Epsilonproteobacteria; Equipment Design; Ericaceae; Excitatory Amino Acid Antagonists; False Negative Reactions; Fatty Acids; Female; Food Analysis; Fresh Water; Gene Expression Regulation, Neoplastic; Glutathione; Graft Occlusion, Vascular; Heart Valve Prosthesis Implantation; Heart Ventricles; HEK293 Cells; Hemolymph; Humans; Hyaluronan Receptors; Hydrogen Peroxide; Hydrothermal Vents; Indoles; Inflammation Mediators; Inhibitory Concentration 50; Insecta; International Normalized Ratio; Isotope Labeling; Itraconazole; Kidney; Kinetics; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lamotrigine; Lanthanoid Series Elements; Limit of Detection; Linear Models; Lipid Peroxidation; Liver; Liver Cirrhosis; Logistic Models; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Malondialdehyde; Mediastinum; Metronidazole; Mice; Mice, Nude; Mice, Transgenic; Microbial Sensitivity Tests; Microscopy, Fluorescence; Middle Aged; Monocytes; Monomeric GTP-Binding Proteins; Multivariate Analysis; Myocytes, Cardiac; Neoplasm Staging; Neoplastic Stem Cells; Neural Pathways; Nitrates; Nucleic Acid Hybridization; Octamer Transcription Factor-3; Odds Ratio; Oxidation-Reduction; Oxidative Stress; Peptidoglycan; Phantoms, Imaging; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Phospholipids; Photolysis; Photosynthesis; Phylogeny; Plant Extracts; Polychaeta; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Care; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyrimidines; Pyrroles; Quorum Sensing; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Reference Values; Regression Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhizosphere; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Rutin; Saphenous Vein; Seawater; Selenium; Semen Preservation; Sensitivity and Specificity; Septal Nuclei; Sequence Analysis, DNA; Serum Albumin; Serum Albumin, Human; Shear Strength; Sodium Pertechnetate Tc 99m; Sodium-Hydrogen Exchangers; Soil Microbiology; SOXB1 Transcription Factors; Spain; Species Specificity; Sperm Motility; Spermatozoa; Spheroids, Cellular; Spores, Fungal; Stroke; Superoxide Dismutase; Swine; Tandem Mass Spectrometry; Technetium Compounds; Technetium Tc 99m Exametazime; Technetium Tc 99m Sestamibi; Temperature; Thiosulfates; Thrombosis; Thyroid Neoplasms; Transducers; Transfection; Transplantation, Heterologous; Treatment Outcome; Triazines; Tumor Burden; Urocortins; Uterine Cervical Neoplasms; Vacuoles; Valproic Acid; Ventral Tegmental Area; Vitamin K 2; Vitamin K Epoxide Reductases; Warfarin; Water Microbiology; Young Adult | 2016 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
[Important aim of statin therapy: ischemic cardiovascular event (stroke)].
Topics: Acute Disease; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Ischemia; Pyrroles; Recurrence; Stroke | 2008 |
What's new in stroke? The top 10 studies of 2006-2008. Part II.
Topics: Anticoagulants; Atorvastatin; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2008 |
[Atorvastatin in secondary prevention].
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Secondary Prevention; Stroke | 2009 |
Review of the SPARCL trial and its subanalyses.
Topics: Age Factors; Atorvastatin; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrroles; Risk Factors; Sex Factors; Stroke | 2009 |
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intracranial Hemorrhages; Primary Prevention; Pyrroles; Risk Factors; Secondary Prevention; Stroke | 2010 |
Current management of symptomatic intracranial stenosis.
Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Pathologic; Endovascular Procedures; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Stents; Stroke; Tetrazoles | 2011 |
Statins for acute ischemic stroke.
Topics: Atorvastatin; Cause of Death; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Neuroprotective Agents; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Ticlopidine | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Japan; Neurology; Physicians; Pioglitazone; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrroles; Secondary Prevention; Stroke; Tetrazoles; Thiazolidinediones; Tissue Plasminogen Activator | 2010 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
[Secondary prevention after ischemic stroke].
Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Carotid Stenosis; Endarterectomy, Carotid; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Smoking Prevention; Stents; Stroke; Vertebral Artery Dissection | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2004 |
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2005 |
Stroke prevention, blood cholesterol and statins.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Factors; Stroke | 2005 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Death, Sudden, Cardiac; Dyslipidemias; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Stroke | 2006 |
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke | 2007 |
Atorvastatin: its clinical role in cerebrovascular prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Stroke | 2007 |
Atorvastatin in prevention of stroke and transient ischaemic attack.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2007 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
Statin therapy and stroke prevention.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Encephalitis; Endothelium, Vascular; Fibrinolytic Agents; Heptanoic Acids; Humans; Lovastatin; Nitric Oxide Synthase; Pyrroles; Stroke | 2001 |
Trials
54 trial(s) available for pyrroles and Stroke
| Article | Year |
|---|---|
Literature Commentary.
Topics: Aged; Aspirin; Humans; Ophthalmology; Piperidines; Pyridines; Pyrroles; Retrospective Studies; Spiro Compounds; Stroke | 2021 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2014 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Prognosis; Pyrroles; Risk Assessment; Stroke; Treatment Outcome; Vascular Diseases | 2014 |
Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up.
Topics: Aged; Atorvastatin; China; Clinical Protocols; Constriction, Pathologic; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pyrroles; Single-Blind Method; Stroke; Vertebrobasilar Insufficiency | 2014 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Topics: Aged; Atorvastatin; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Kidney; Male; Middle Aged; Pyrroles; Stroke | 2014 |
Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Case-Control Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Ischemic Attack, Transient; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Stroke; Ultrasonography | 2015 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
Topics: Adult; Aged; Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyrroles; Stroke | 2015 |
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Topics: Apolipoprotein A-I; Atorvastatin; Blood Pressure; Cholesterol; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Male; Middle Aged; Pyrroles; Reproducibility of Results; Sex Characteristics; Sex Factors; Stroke; Treatment Outcome; Triglycerides | 2008 |
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Triglycerides | 2009 |
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2009 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Risk Factors; Secondary Prevention; Stroke; Treatment Outcome; Triglycerides; Young Adult | 2009 |
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke | 2009 |
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Cholesterol; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Stroke | 2010 |
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Retrospective Studies; Stroke; Time Factors | 2011 |
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome | 2011 |
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome | 2011 |
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Cholesterol; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Stroke; Triglycerides; Young Adult | 2011 |
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome | 2012 |
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Brain Ischemia; Cerebral Infarction; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Monitoring, Physiologic; Pyrroles; Sample Size; Stroke; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2012 |
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cardiopulmonary Resuscitation; Cholesterol, LDL; Death, Sudden, Cardiac; Female; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk; Sex Factors; Stroke | 2012 |
Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase.
Topics: Aged; Atorvastatin; Chromatography, High Pressure Liquid; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Nitric Oxide; Pyrroles; Stem Cells; Stroke; Vascular Endothelial Growth Factor A | 2012 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome | 2002 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Stroke | 2003 |
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke; Time Factors | 2004 |
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment | 2004 |
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Placebos; Pyrroles; Stroke; Treatment Outcome | 2005 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2004 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke | 2005 |
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke | 2006 |
High-dose atorvastatin after stroke or transient ischemic attack.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Proportional Hazards Models; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Quinapril; Risk Factors; Stroke; Tetrahydroisoquinolines; Time Factors | 2006 |
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke | 2006 |
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome | 2007 |
Statin treatment withdrawal in ischemic stroke: a controlled randomized study.
Topics: Acute Disease; Aged; Atorvastatin; Brain Ischemia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neuroprotective Agents; Odds Ratio; Pyrroles; Risk Factors; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Withholding Treatment | 2007 |
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2007 |
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrroles; Risk Factors; ROC Curve; Serum Amyloid A Protein; Stroke | 2008 |
SPARCL: the glimmer of statins for stroke risk reduction.
Topics: Atorvastatin; Coronary Disease; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Stroke | 2007 |
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke | 2008 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
Other Studies
104 other study(ies) available for pyrroles and Stroke
| Article | Year |
|---|---|
Wnt canonical pathway activator TWS119 drives microglial anti-inflammatory activation and facilitates neurological recovery following experimental stroke.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL; Microglia; Pyrimidines; Pyrroles; Recovery of Function; Stroke; Wnt Signaling Pathway | 2019 |
Targeting GSNOR for functional recovery in a middle-aged mouse model of stroke.
Topics: Aging; Alcohol Dehydrogenase; Animals; Benzamides; Disease Models, Animal; Drug Delivery Systems; Male; Mice; Mice, Inbred C57BL; Pyrroles; Recovery of Function; Stroke | 2020 |
GSK-3β as a target for protection against transient cerebral ischemia.
Topics: Animals; beta Catenin; Blood-Brain Barrier; Brain; Disease Models, Animal; Gene Expression Regulation; Glycogen Synthase Kinase 3 beta; Humans; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Pyrimidines; Pyrroles; Rats; Stroke; Wnt Signaling Pathway; Zonula Occludens-1 Protein | 2017 |
Electrical preconditioning of stem cells with a conductive polymer scaffold enhances stroke recovery.
Topics: Animals; Brain Infarction; Electric Conductivity; Electric Stimulation; Gene Expression Regulation; Humans; Male; Neural Stem Cells; Polymers; Pyrroles; Rats, Nude; Recovery of Function; RNA, Messenger; Stroke; Tissue Scaffolds; Vascular Endothelial Growth Factor A | 2017 |
Inhibition of VEGF Signaling Reduces Diabetes-Exacerbated Brain Swelling, but Not Infarct Size, in Large Cerebral Infarction in Mice.
Topics: Animals; Blood Glucose; Brain Edema; Brain Ischemia; Cerebral Infarction; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucose Tolerance Test; Indoles; Insulin; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Proteoglycans; Pyrroles; RNA, Messenger; Signal Transduction; Stroke; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2019 |
Compliance and echographic carotid plaque evolution in patients with acute ischemic stroke treated with atorvastatin according to usual care.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Medication Adherence; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Spain; Stroke; Triglycerides; Ultrasonography | 2014 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.
Topics: Animals; Atorvastatin; Cerebral Cortex; Disease Models, Animal; Gene Expression; Heptanoic Acids; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase Type II; PPAR alpha; Pyrroles; Stroke; Vascular Cell Adhesion Molecule-1 | 2014 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Life Style; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Risk Factors; Secondary Prevention; Stroke; Ticlopidine | 2014 |
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Polycythemia Vera; Pyrroles; Recurrence; Stroke; Treatment Outcome | 2015 |
Delayed inhibition of VEGF signaling after stroke attenuates blood-brain barrier breakdown and improves functional recovery in a comorbidity-dependent manner.
Topics: Animals; Blood-Brain Barrier; Brain; Capillaries; Dendritic Spines; Diabetes Mellitus, Experimental; Disease Models, Animal; Endothelial Cells; Gene Expression; Indoles; Infarction; Insulin; Mice; Permeability; Pyrroles; Recovery of Function; Signal Transduction; Stroke; Synapses; Transcytosis; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Ask the doctor. I am 61 and had been on atorvastatin for 10 years with no problems. Recently, I've had disabling muscle pain with both the generic atorvastatin and the brand-name version, Lipitor. My doctor says that I can no longer take statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Health Behavior; Heptanoic Acids; Humans; Middle Aged; Muscle, Skeletal; Pyrroles; Rhabdomyolysis; Stroke | 2014 |
Possible involvement of basic FGF in the upregulation of PDGFRβ in pericytes after ischemic stroke.
Topics: Animals; Brain; Brain Ischemia; Cell Hypoxia; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Hydrogen-Ion Concentration; Infarction, Middle Cerebral Artery; Male; Mice, 129 Strain; Mice, Inbred C57BL; Pericytes; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Stroke; Up-Regulation | 2016 |
GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Cerebral Hemorrhage; Claudin-3; Glycogen Synthase Kinase 3 beta; Infarction, Middle Cerebral Artery; Male; Permeability; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats, Sprague-Dawley; Stroke; Tissue Plasminogen Activator; Wnt Signaling Pathway; Zonula Occludens-1 Protein | 2016 |
NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Epilepsy; Humans; Neuralgia; Pyrroles; Receptors, AMPA; Stroke; Tetrahydroisoquinolines; Treatment Outcome | 2017 |
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor | 2008 |
Atorvastatin enhances hypothermia-induced neuroprotection after stroke.
Topics: Animals; Atorvastatin; Brain Infarction; CD11b Antigen; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnetic Resonance Imaging; Male; Neurologic Examination; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Stroke | 2008 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Risk Assessment; Stroke | 2009 |
Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2008 |
Hemorrhagic stroke in the SPARCL study.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Intracranial Hemorrhages; Lipoproteins, LDL; Male; Pyrroles; Risk Factors; Stroke | 2008 |
Binder wars.
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Polyamines; Pyrroles; Sevelamer; Stroke | 2008 |
[Statins and stroke].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Neovascularization, Physiologic; Pyrroles; Stroke | 2008 |
The cost of stroke prevention.
Topics: Atorvastatin; Clinical Trials as Topic; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary Body; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Light Coagulation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Ophthalmic Artery; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Stroke; Ultrasonography | 2008 |
Statins: not just for the young or the faint of heart.
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke | 2009 |
Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Arteries; Constriction, Pathologic; Disease Progression; Female; Heptanoic Acids; Humans; Hyperlipidemias; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Secondary Prevention; Sex Distribution; Stroke; Treatment Outcome; Vertebrobasilar Insufficiency | 2009 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Computer Simulation; Cost-Benefit Analysis; Databases, Factual; Female; Health Services; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Saskatchewan; Secondary Prevention; Stroke; Survival Analysis; United States; Young Adult | 2009 |
Statins and gender-related difference in endothelial function in cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Heptanoic Acids; Humans; Ischemic Attack, Transient; Outcome Assessment, Health Care; Pyrroles; Stroke; Treatment Outcome | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Hemorrhage; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Iatrogenic Disease; Ischemic Attack, Transient; Pyrroles; Risk Assessment; Risk Factors; Stroke | 2009 |
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agents; Heptanoic Acids; Immunohistochemistry; Intracranial Embolism; Male; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Stroke; Time Factors; Tissue Plasminogen Activator | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Secondary Prevention; Stroke | 2009 |
The results support the use of atorvastatin in elderly patients with recent stroke or TIA.
Topics: Aged; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Stroke | 2009 |
Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Baroreflex; Heptanoic Acids; Hypertension; Injections, Intraventricular; Male; Medulla Oblongata; NADP; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System | 2010 |
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2009 |
Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Apoptosis; Calpain; Caspase 3; Cell Proliferation; Cerebral Arteries; Disease Models, Animal; Endothelial Cells; Indoles; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Necrosis; Neovascularization, Physiologic; Pyrroles; Rats; Rats, Sprague-Dawley; Stroke; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability.
Topics: Acute Disease; Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Atorvastatin; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Capillary Permeability; Down-Regulation; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Phospholipases A2, Cytosolic; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke; Time Factors | 2010 |
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2010 |
Charting new territory by simulated modeling of a clinical trial.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
Topics: Age Factors; Aged; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Sex Factors; Stroke; Treatment Outcome | 2010 |
Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Neuroprotective Agents; Pyrroles; Retrospective Studies; Severity of Illness Index; Simvastatin; Statistics as Topic; Stroke; Stroke Rehabilitation; Treatment Outcome | 2010 |
High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
Topics: Atorvastatin; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pakistan; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2010 |
[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Models, Theoretical; Myocardial Infarction; Placebos; Pyrroles; Risk Factors; Secondary Prevention; Spain; Stroke; Treatment Outcome; Young Adult | 2010 |
Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Male; Neurons; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria; Motor Activity; Movement Disorders; Neurons; Organ Specificity; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Stroke; Tetrazoles | 2011 |
Statins before stents: does an ounce of prevention improve outcomes?
Topics: Atorvastatin; Biomarkers; Carotid Artery Diseases; Creatine Kinase, MB Form; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Preoperative Care; Pyrroles; Risk Assessment; Risk Factors; Stents; Stroke; Treatment Outcome; Troponin I; Troponin T | 2010 |
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nerve Degeneration; Neuroprotective Agents; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male physicians.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Risk Reduction Behavior; Stroke; Time Factors; Treatment Outcome | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid Stenosis; Clopidogrel; Colitis, Ulcerative; Female; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Lipoprotein(a); Magnetic Resonance Imaging; Middle Aged; Pyrroles; Risk Factors; Stroke; Thrombosis; Ticlopidine; Ultrasonography | 2011 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries | 2011 |
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Stroke | 2012 |
Small unruptured partially thrombosed aneurysms and stroke: report of three cases and review of the literature.
Topics: Aspirin; Atorvastatin; Craniotomy; Echocardiography, Transesophageal; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Intracranial Aneurysm; Intracranial Embolism; Male; Middle Aged; Neurosurgical Procedures; Paresis; Pyrroles; Stroke; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color | 2012 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Ischemia; Lipoprotein Lipase; Male; Middle Aged; Minisatellite Repeats; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Prognosis; Pyrroles; Risk Factors; Stroke | 2012 |
Efficacy of combined atorvastatin and sildenafil in promoting recovery after ischemic stroke in mice.
Topics: Animals; Atorvastatin; Behavior, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Neuropsychological Tests; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrroles; Recovery of Function; Sildenafil Citrate; Stroke; Sulfones | 2013 |
Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: follow-up of the ATHEROMA trial.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Contrast Media; Dextrans; Diabetes Complications; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Macrophage Activation; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2012 |
Sudden bilateral anterior cerebral infarction: unusual stroke associated with unusual vascular anomalies.
Topics: Adult; Aspirin; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Internal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Anterior Cerebral Artery; Magnetic Resonance Angiography; Male; Platelet Aggregation Inhibitors; Pyrroles; Stroke | 2013 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2013 |
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Europe; Guideline Adherence; Heptanoic Acids; Humans; Myocardial Infarction; Practice Guidelines as Topic; Preventive Health Services; Pyrroles; Societies; Stroke; United Kingdom | 2002 |
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; Brain; Genetic Predisposition to Disease; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Lipids; Male; Myocardium; Neural Inhibition; Nitric Oxide Synthase; Norepinephrine; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Sympathetic Nervous System; Up-Regulation | 2003 |
Withdrawal of statin treatment abrogates stroke protection in mice.
Topics: Animals; Aorta; Atorvastatin; Bleeding Time; Blood Coagulation; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet Activation; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Stroke; Substance Withdrawal Syndrome; Vena Cava, Inferior; Venous Thrombosis | 2003 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke.
Topics: Animals; Antibodies; Atorvastatin; Brain; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Neovascularization, Physiologic; Neuronal Plasticity; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Stroke; Synapses; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Drug Utilization; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Registries; Stroke; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Evaluation; Heptanoic Acids; Humans; Hypertension; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin; Stroke; Treatment Outcome | 2003 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone | 2004 |
Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat.
Topics: Animals; Atorvastatin; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Pyrroles; Rats; Rats, Inbred SHR; Stroke | 2004 |
[Statins and hypertension].
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hypertension; Pyrroles; Stroke | 2004 |
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice.
Topics: Animals; Atorvastatin; Brain-Derived Neurotrophic Factor; Cell Movement; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Neovascularization, Physiologic; Neuronal Plasticity; Pyrroles; Rats; Recovery of Function; Stem Cells; Stroke; Vascular Endothelial Growth Factor A | 2005 |
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2005 |
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Topics: Animals; Atorvastatin; Brain Ischemia; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Simvastatin; Stroke; Tissue Plasminogen Activator | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
The logistic transform for bounded outcome scores.
Topics: Anticholesteremic Agents; Atorvastatin; Computer Simulation; Coronary Disease; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Models, Statistical; Patient Compliance; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Tissue Plasminogen Activator | 2007 |
MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Data Interpretation, Statistical; Heptanoic Acids; Intracranial Embolism; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Microcirculation; Microscopy, Fluorescence; Plasminogen Activators; Pyrroles; Rats; Rats, Wistar; Recombinant Proteins; Stroke | 2006 |
[After TIA and stroke: a statin for secondary prevention?].
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Placebos; Pyrroles; Recurrence; Stroke; Time Factors | 2006 |
Stroke--an equal opportunity for the initiation of statin therapy.
Topics: Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Stroke | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Atorvastatin for stroke prevention.
Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Stroke; Transaminases | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Severity of Illness Index; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Conflict of Interest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Risk; Secondary Prevention; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Stroke; Survival Analysis | 2006 |
Statin effective in preventing recurrent stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Stroke | 2006 |
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Recurrence; Risk Factors; Stroke | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Atorvastatin; Brain; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Metabolism; Male; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Time; Time Factors; Treatment Outcome | 2007 |
Discontinuation of statin therapy and clinical outcome after ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Simvastatin; Stroke; Substance Withdrawal Syndrome | 2007 |
Higher dose of statin medication may be better for older adults.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Stroke | 2007 |
Atorvastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Disease Models, Animal; Heptanoic Acids; Homeodomain Proteins; Male; Middle Cerebral Artery; Neurons; Presenilin-1; Pyrroles; Rats; Rats, Wistar; Receptor, Notch1; Signal Transduction; Stem Cells; Stroke; Transcription Factor HES-1 | 2008 |
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke | 2008 |
[Stroke due to spontaneous calcified cerebral embolus as presenting feature of calcified aortic stenosis].
Topics: Aged, 80 and over; Anterior Cerebral Artery; Aortic Valve; Aortic Valve Stenosis; Aspirin; Atorvastatin; Calcinosis; Heptanoic Acids; Humans; Intracranial Embolism; Male; Pyrroles; Stroke; Tomography, X-Ray Computed | 2008 |
Natural statins and stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fibrinogen; Heptanoic Acids; Humans; Pyrroles; Risk Factors; Stroke | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |